Bipin Dalmia

Vice President, Business Development & New Product Assessment

Bipin Dalmia is responsible for all Ferring US business development activities and is a key member of the Ferring Global Business Development group.

Bipin has over 25 years of experience in pharmaceuticals and biotechnology industries, starting as a research scientist and transitioning early in his career to licensing and business development. Before joining Ferring in 2012, he held roles of rapidly increasing responsibilities at Biolex Therapeutics, Syngenta and Novartis. During his 20 year business development career, he has led to conclusion over 50 transactions, both on the buy and sell sides, in biotech, specialty pharma and big pharma across several therapeutic areas and development stages.

Bipin holds a MBA degree from Drake University in Des Moines, Iowa, and a Ph.D. in Chemical Engineering from Iowa State University in Ames, Iowa.

This site contains material about Ferring Pharmaceuticals Inc. (hereinafter "Ferring") and its various products that may be of interest to Ferring's employees and customers, as well as to members of the health care community and the general public. Please feel free to browse this web site. Your access and use of the information contained herein is subject to the following terms and conditions and all applicable laws. By accessing and browsing this web site, you accept, without limitation or qualification, these terms and conditions and acknowledge that they supersede any other agreement between you and Ferring.

All information on this site is intended for US audiences only.

CERVIDIL, CLENPIQ, ENDOMETRIN, EUFLEXXA, FIRMAGON, MENOPUR, NOCDURNA, NOVAREL, and ZOMACTON are registered trademarks of Ferring B.V. INVOCELL is a registered trademark of INVO BioScience.

©2008-2019 Ferring Pharmaceuticals.  US--1900006